Financials data is unavailable for this security.
View more
Year on year Vanda Pharmaceuticals Inc 's revenues fell -24.27% from 254.38m to 192.64m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 6.28m to 2.51m, a -60.02% decrease.
| Gross margin | 93.62% |
|---|---|
| Net profit margin | -8.59% |
| Operating margin | -19.64% |
| Return on assets | -2.55% |
|---|---|
| Return on equity | -3.02% |
| Return on investment | -2.95% |
More ▼
Cash flow in USDView more
In 2023, Vanda Pharmaceuticals Inc did not generate a significant amount of cash. However, the company earned 12.80m from its operations for a Cash Flow Margin of 6.65%. In addition the company used 12.06m on investing activities while cash flow from financing was even.
| Cash flow per share | -0.1564 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.28 |
|---|---|
| Tangible book value per share | 7.30 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.85 |
|---|---|
| Quick ratio | 4.84 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -60.42%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -37.98 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -239.61 |
